Comparative safety of imeglimin versus sitagliptin in Japanese patients with type 2 diabetes: A pharmacy-based retrospective cohort study
Nao Suzuki, Nobuhiro Ooba, Rie Nakajima, Kasumi Takabatake, Masahiro Saita, Eiji Kawakami, Michiyo Kawana, Daiki Watanabe · 2026
Read Comparative safety of imeglimin versus sitagliptin in Japanese patients with type 2 diabetes: A pharmacy-based retrospective cohort study by Nao Suzuki, Nobuhiro Ooba, Rie Nakajima, Kasumi Takabatake, Masahiro Saita, Eiji Kawakami, Michiyo Kawana, Daiki Watanabe (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0359960.txt.
Description
Nao Suzuki and eight colleagues published this research article in PLOS ONE in 2026. It compares the safety of two diabetes drugs, imeglimin and sitagliptin, for patients in Japan who live with type 2 diabetes. The work is a retrospective cohort study based on pharmacy records, looking back at real patients.
Comparing safety in everyday practice matters because trial patients are often healthier than clinic patients. Pharmacy records capture the people actually taking these medicines, including those with other conditions. Doctors choosing between newer and established diabetes drugs in Japan can use real-world safety comparisons like this one alongside trial evidence.
Catalog record
| CREATOR | Nao Suzuki, Nobuhiro Ooba, Rie Nakajima, Kasumi Takabatake, Masahiro Saita, Eiji Kawakami, Michiyo Kawana, Daiki Watanabe |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34239 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |